viewNetScientific PLC

NetScientific on the rise again after PDS cancer trial

“The data provide early evidence of notable clinical activity, and we saw effective tumour regression in these patients"

NetScientific PLC -

NetScientific PLC (LON:NSCI) portfolio company, PDS Biotechnology (NASDAQ:PDSB) said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression.

Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, the data showed results of a phase PDS’s candidate PDS0101 in combination with two immune-modulating agents on 25 patients.

Dr Lauren Wood, PDS’ chief medical officer, said: “The data provide early evidence of notable clinical activity, and we saw effective tumour regression in these patients"

The achievement of a 67% tumour reduction among all HPV16-positive cancer patients supports further clinical investigation of the Versamune platform's potential ability to induce high levels of tumour-specific CD8+ killer T-cells that attack cancer, she added.

 "The interim data demonstrating that this response was limited only to patients with HVP16-positive cancer, and also the fact that all responding patients who have stayed on treatment continue to show ongoing responses after a median duration of 8 months solidifies our belief that PDS0101's ability to generate a robust, targeted T-cell response."

This might have the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV16-associated cancers who have limited treatment options, Wood added. 

Shares in NetScientific, which holds 5.75% of PDS, rose 33% to 199p, effectively meaning the shares have doubled in two days.

The share price had already rocketed yesterday on news yesterday from another portfolio company, Proaxis, which struck a licensing deal with AstraZeneca PLC (LON:AZN) over the validation and global commercialisation of an assay associated with coronavirus vaccines.

Quick facts: NetScientific PLC


Price: 113.5 GBX

Market Cap: £23.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


NetScientific invest £1m in Martlet Capital 'fitting with strategy to...

NetScientific PLC (AIM:NSCI, FRA:NTK1) (AIM:NSCI, FRA:NTK1) chief executive, Dr Ilian Iliev joins Proactive after announcing their news to invest an initial £1mln in Martlet Capital, which has been set up to acquire a portfolio of minority interests in growth companies operating in the Cambridge...

3 days, 10 hours ago

2 min read